<DOC>
	<DOCNO>NCT02485613</DOCNO>
	<brief_summary>Although use bortezomib report efficacy amyloid light chain ( AL ) amyloidosis , role bortezomib dexamethasone ( BD ) first-line treatment patient AL amyloidosis determine . In study , investigator evaluate efficacy safety BD first-line treatment patient AL amyloidosis .</brief_summary>
	<brief_title>Bortezomib Immunoglobulin Light Chain ( AL ) Amyloidosis</brief_title>
	<detailed_description>This study include patient newly diagnose AL amyloidosis treat BD regimen Jinling hospital . The AL amyloidosis diagnosis confirm renal biopsy , assessment organ involvement base consensus criterion . The clinical laboratory data collect begin cycle every 3 month thereafter . The initial BD regimen include bortezomib ( 1.3 mg/m2 i.v . ) dexamethasone ( 40 mg i.v . ) twice weekly 2 week ( day 1 , 4 , 8 , 11 ) , follow 10-day rest period ( day 12-21 ) . The investigator evaluate efficacy safety BD first-line treatment patient AL amyloidosis .</detailed_description>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulin Light Chains</mesh_term>
	<mesh_term>Bence Jones Protein</mesh_term>
	<criteria>Female male patient age 18 80 year Renal type biopsy use diagnose AL amyloidosis Understand voluntarily sign informed consent form ECOG score 03 point Adequate residual organ function Receiving investigational agent would consider treatment primary neoplasm Grade 3 sensory grade 1 painful peripheral neuropathy Known hypersensitivity bortezomib , boron mannitol Cardiac syncope , uncompensated New York Heart Association ( NYHA ) Class 3 4 congestive heart failure Clinically overt multiple myeloma Pregnant nursing woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>